國立虎尾科技大學 |

Kala Azar in South Asia = Current Status and Sustainable Challenges /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Kala Azar in South Asia/ edited by E. Noiri, T.K. Jha.
Reminder of title:	Current Status and Sustainable Challenges /
other author:	Noiri, E.
Description:	XX, 309 p. 85 illus., 54 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Parasitology. -
Online resource:	https://doi.org/10.1007/978-3-319-47101-3
ISBN:	9783319471013

Kala Azar in South Asia = Current Status and Sustainable Challenges /
Kala Azar in South AsiaCurrent Status and Sustainable Challenges /[electronic resource] :edited by E. Noiri, T.K. Jha. - 2nd ed. 2016. - XX, 309 p. 85 illus., 54 illus. in color.online resource.

Preface. Part I Introduction into Kala-Azar Pathology and Mechanism of Disease in Kala-Azar -- Treatment of Post-kala-azar Dermal Leishmaniasis -- Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System -- Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries -- Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance -- A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance -- Treatment of Post-kala-azar Dermal Leishmaniasis -- Combination Therapy for Leishmaniasis -- Vaccine Development for Leishmaniasis -- Siccanin is a novel selective inhibitor of trypanosomatid complex II (succinate-ubiquinone reductase) and a potent broad-spectrum anti-trypanosomatid drug candidate -- Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent -- Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program -- Changes of Leishmania antigens in kala-azar patients’ urine after treatment -- Potentiality of Urinary L-FABP Tests to Kala-azar Disease Management -- Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine -- Loop-mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis -- Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis -- Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis -- Part V Knowledge and Practice for Vector Control in Kala-Azar -- Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh -- The efficacy of long lasting insecticidal nets for leishmaniasis in Asia -- Environmental change and kala-azar with particular reference to Bangladesh -- Part VI. New Challenges in the Kala-azar Elimination Programme -- Drug Safety Monitoring for Liposomal Amphotericin B -- Resolution Mapping of Kala-azar Hot Spots Using GPS Logger and Urinary Antibody Measurements -- Geography and Reality of Kala-azar Endemic in Bangladesh, Analysis Using GIS and Urine-based Mass Screening -- Animal Models of Visceral Leishmaniasis and Applicability to Disease Control -- Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. Index.

Visceral leishmaniasis (VL), (also known as black fever or Kala-azar) is a life-threatening disease first reported from the Indian subcontinent. VL ranks as the world’s second largest parasitic disease killer and is a neglected tropical disease. Most of those infected by this life-threatening disease are uneducated daily wagers working to support their families, and vectors easily disseminate the disease to their neighbors. Owing to recent involvement of stakeholders, the number of patients is decreasing, but eradication remains a distant goal. This second edition presents latest reports of visceral Leishmaniasis by specialists working at the forefront of the endemic areas in Indian subcontinent. It also introduces vaccine development and inhibitors to Trypanosomatidae; some of them describing feasibility studies in visceral Leishmaniasis for the first time. Recent progress of the Science and Technology Research Partnership for Sustainable Development (SATREPS) is also reviewed and the contents share this collaborative research from the forefront of endemic sites in Bangladesh. Widely covering basic, clinical, epidemiological and entomological aspects, this volume will be of great interest to dedicated researchers interested in Leishmaniasis and to experts of NTDs in global health. There is a tide in the affairs of men. Which, taken at the flood, leads on to fortune; Omitted, all the voyage of disease control is bound in shallows and in miseries. ~modified from Shakespeare ~.

ISBN: 9783319471013

Standard No.: 10.1007/978-3-319-47101-3doiSubjects--Topical Terms:

669054
Parasitology.

LC Class. No.: QR251-255

Dewey Class. No.: 616.96

Kala Azar in South Asia = Current Status and Sustainable Challenges /
LDR:05143nam a22003855i 4500 001 980870
003 DE-He213
005 20200630032518.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319471013 $9 978-3-319-47101-3
024 7 $a 10.1007/978-3-319-47101-3 $2 doi
035 $a 978-3-319-47101-3
050 4 $a QR251-255
072 7 $a MMFP $2 bicssc
072 7 $a MED103000 $2 bisacsh
072 7 $a MKFP $2 thema
082 0 4 $a 616.96 $2 23
245 1 0 $a Kala Azar in South Asia $h [electronic resource] : $b Current Status and Sustainable Challenges / $c edited by E. Noiri, T.K. Jha.
250 $a 2nd ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XX, 309 p. 85 illus., 54 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Preface. Part I Introduction into Kala-Azar Pathology and Mechanism of Disease in Kala-Azar -- Treatment of Post-kala-azar Dermal Leishmaniasis -- Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System -- Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries -- Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance -- A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance -- Treatment of Post-kala-azar Dermal Leishmaniasis -- Combination Therapy for Leishmaniasis -- Vaccine Development for Leishmaniasis -- Siccanin is a novel selective inhibitor of trypanosomatid complex II (succinate-ubiquinone reductase) and a potent broad-spectrum anti-trypanosomatid drug candidate -- Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent -- Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program -- Changes of Leishmania antigens in kala-azar patients’ urine after treatment -- Potentiality of Urinary L-FABP Tests to Kala-azar Disease Management -- Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine -- Loop-mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis -- Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis -- Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis -- Part V Knowledge and Practice for Vector Control in Kala-Azar -- Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh -- The efficacy of long lasting insecticidal nets for leishmaniasis in Asia -- Environmental change and kala-azar with particular reference to Bangladesh -- Part VI. New Challenges in the Kala-azar Elimination Programme -- Drug Safety Monitoring for Liposomal Amphotericin B -- Resolution Mapping of Kala-azar Hot Spots Using GPS Logger and Urinary Antibody Measurements -- Geography and Reality of Kala-azar Endemic in Bangladesh, Analysis Using GIS and Urine-based Mass Screening -- Animal Models of Visceral Leishmaniasis and Applicability to Disease Control -- Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis. Index.
520 $a Visceral leishmaniasis (VL), (also known as black fever or Kala-azar) is a life-threatening disease first reported from the Indian subcontinent. VL ranks as the world’s second largest parasitic disease killer and is a neglected tropical disease. Most of those infected by this life-threatening disease are uneducated daily wagers working to support their families, and vectors easily disseminate the disease to their neighbors. Owing to recent involvement of stakeholders, the number of patients is decreasing, but eradication remains a distant goal. This second edition presents latest reports of visceral Leishmaniasis by specialists working at the forefront of the endemic areas in Indian subcontinent. It also introduces vaccine development and inhibitors to Trypanosomatidae; some of them describing feasibility studies in visceral Leishmaniasis for the first time. Recent progress of the Science and Technology Research Partnership for Sustainable Development (SATREPS) is also reviewed and the contents share this collaborative research from the forefront of endemic sites in Bangladesh. Widely covering basic, clinical, epidemiological and entomological aspects, this volume will be of great interest to dedicated researchers interested in Leishmaniasis and to experts of NTDs in global health. There is a tide in the affairs of men. Which, taken at the flood, leads on to fortune; Omitted, all the voyage of disease control is bound in shallows and in miseries. ~modified from Shakespeare ~.
650 0 $a Parasitology. $3 669054
650 0 $a Drug resistance. $3 872072
650 0 $a Veterinary medicine. $3 785002
650 0 $a Laboratory medicine. $3 1254567
650 0 $a Nephrology. $3 668354
650 2 4 $a Drug Resistance. $3 782695
650 2 4 $a Veterinary Medicine/Veterinary Science. $3 1114372
650 2 4 $a Laboratory Medicine. $3 673604
700 1 $a Noiri, E. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 783819
700 1 $a Jha, T.K. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 783818
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319436128
776 0 8 $i Printed edition: $z 9783319436111
856 4 0 $u https://doi.org/10.1007/978-3-319-47101-3
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)